Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Tax Provisions: 2014-2023

Historic Tax Provisions for Lineage Cell Therapeutics (LCTX) over the last 2 years, with Mar 2023 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Tax Provisions was N/A to -$1.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was -$16.3 million, marking a year-over-year change of. This contributed to the annual value of -$1.8 million for FY2023, which is 433.27% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Tax Provisions stood at -$1.8 million for Q1 2023, which was down 433.27% from $541,000 recorded in Q3 2022.
  • In the past 5 years, Lineage Cell Therapeutics' Tax Provisions ranged from a high of $4.4 million in Q1 2019 and a low of -$14.0 million during Q4 2019.
  • Its 3-year average for Tax Provisions is -$758,000, with a median of -$1.0 million in 2021.
  • Data for Lineage Cell Therapeutics' Tax Provisions shows a peak YoY surged of 153.46% (in 2022) over the last 5 years.
  • Quarterly analysis of 4 years shows Lineage Cell Therapeutics' Tax Provisions stood at -$14.0 million in 2019, then reached -$1.0 million in 2021, then surged by 153.46% to $541,000 in 2022, then reached -$1.8 million in 2023.
  • Its Tax Provisions was -$1.8 million in Q1 2023, compared to $541,000 in Q3 2022 and -$1.0 million in Q3 2021.